BOSTON--(BUSINESS WIRE)--NMT Medical, Inc. (NASDAQ: NMTI) announced today that, upon recommendation of the CLOSURE I Executive Committee, it will commence data analysis for its landmark patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) clinical trial – originally scheduled for the fall of 2010 – in April 2010. At that time, 99.4% of all patient follow-up months will have been completed and 95.1% of patients will have completed the two-year follow-up. The results of the analysis are anticipated during the third quarter of 2010 at which point the trial will be complete, with 100% of the randomized patient follow-up available. If the results prove positive for device closure, the Company will be in a position to submit a Pre-Market Approval (PMA) application for its STARFlex® device for the stroke and TIA indication to the U.S. Food and Drug Administration (FDA).
